LEX Diagnostics
Chris Hole has a diverse work experience spanning over several companies and roles. Chris started their career in 1988 as a Trainee at Rolls-Royce and completed the program in 1991. Chris then worked at Oxford Instruments as a Development Engineer from 1995 to 1996. In 1996, they became a Royal Society Research Fellow at the National Research Institute for Metals. From 1997 to 2004, they held various roles, including design engineering and marketing, at REMEC (now acquired by Commscope & Cobham). In 2004, they joined Hypres as VP Business Development & Chief System Engineer in the Commercial Division and stayed until 2008. From 2008 to 2020, they worked at The Technology Partnership as a Senior Consultant. Most recently, in 2020, they joined LEX Diagnostics as the VP Commercial.
Chris Hole's education history includes a Bachelor of Science (BSc) degree in Physics from the University of Bristol, which they obtained from 1989 to 1992. Subsequently, from 1992 to 1995, they pursued a Doctor of Philosophy (DPhil) in Solid State Physics / Materials at the University of Oxford.
LEX Diagnostics
LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care. Having solved the PCR cost problem, LEX focuses tightly on nasal and oral samples, and on viral pathogens, to avoid the other high-cost elements of traditional molecular diagnostic products. LEX Diagnostics is a spin-out from TTP plc, atechnology development company in the life science and medical device sector. The origins of the LEX technology lie in an internal R&D project to reduce the time it takes to get a result from a PCR test. It formed a company when it became clear the solution also reduced the cost and size of any diagnostic device using it.LEX Diagnostics was founded in 2020 and is based in Melbourn, United Kingdom.